CA1292690C - Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic sequentially homologous peptide - Google Patents

Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic sequentially homologous peptide

Info

Publication number
CA1292690C
CA1292690C CA000545494A CA545494A CA1292690C CA 1292690 C CA1292690 C CA 1292690C CA 000545494 A CA000545494 A CA 000545494A CA 545494 A CA545494 A CA 545494A CA 1292690 C CA1292690 C CA 1292690C
Authority
CA
Canada
Prior art keywords
vaccine
inactivated
protein
picornavirus
poliovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000545494A
Other languages
English (en)
French (fr)
Inventor
Antonius Ludovicus Van Wezel
Antonius Gerardus Hazendonk
Eduard Coen Beuvery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlanden Staat
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Application granted granted Critical
Publication of CA1292690C publication Critical patent/CA1292690C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA000545494A 1986-08-27 1987-08-27 Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic sequentially homologous peptide Expired - Lifetime CA1292690C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/900,739 US4946676A (en) 1986-08-27 1986-08-27 Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide
US900,739 1986-08-27

Publications (1)

Publication Number Publication Date
CA1292690C true CA1292690C (en) 1991-12-03

Family

ID=25413018

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000545494A Expired - Lifetime CA1292690C (en) 1986-08-27 1987-08-27 Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic sequentially homologous peptide

Country Status (10)

Country Link
US (1) US4946676A (enExample)
EP (1) EP0257721B1 (enExample)
JP (1) JPS63132844A (enExample)
AT (1) ATE71534T1 (enExample)
CA (1) CA1292690C (enExample)
DE (1) DE3776034D1 (enExample)
DK (1) DK169276B1 (enExample)
ES (1) ES2032812T3 (enExample)
GR (1) GR3003754T3 (enExample)
NO (1) NO873593L (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797270B1 (en) * 1989-03-16 2004-09-28 Center For Blood Research, Inc. Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
US20040002058A1 (en) * 2001-06-21 2004-01-01 Uab Research Foundation Chimeric capsid proteins and uses thereof
WO2003000855A2 (en) * 2001-06-21 2003-01-03 Uab Research Foundation Chimeric capsid proteins and uses thereof
US20090142364A1 (en) * 2007-08-30 2009-06-04 Fedor Alexandrovich Brovko Method for finding novel peptide immunostimulatory adjuvants, compositions and methods of use
US11160857B2 (en) 2015-06-15 2021-11-02 Emory University Multivalent enterovirus vaccine compositions and uses related thereto
EP3432902B8 (en) * 2016-03-20 2025-12-17 The Trustees of The University of Pennsylvania Codon optimization and ribosome profiling for increasing transgene expression in chloroplasts of higher plants

Also Published As

Publication number Publication date
DK446287A (da) 1988-02-28
JPS63132844A (ja) 1988-06-04
DK446287D0 (da) 1987-08-26
NO873593D0 (no) 1987-08-26
ES2032812T3 (es) 1993-03-01
US4946676A (en) 1990-08-07
EP0257721B1 (en) 1992-01-15
EP0257721A3 (en) 1988-06-08
NO873593L (no) 1988-02-29
EP0257721A2 (en) 1988-03-02
DK169276B1 (da) 1994-10-03
ATE71534T1 (de) 1992-02-15
GR3003754T3 (enExample) 1993-03-16
DE3776034D1 (de) 1992-02-27

Similar Documents

Publication Publication Date Title
AU653387B2 (en) Antigen-presenting chimaeric protein
US4605512A (en) Small peptides with the specificity of foot and mouth disease viral antigens
US20090239265A1 (en) Virus like particles
US5019383A (en) Fatty acid carriers for synthetic peptides
Francis Peptide vaccines for viral diseases
CA1292690C (en) Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic sequentially homologous peptide
AU674983B2 (en) Vaccine compositions
Redmond et al. Rotavirus particles function as immunological carriers for the delivery of peptides from infectious agents and endogenous proteins
Murray Application of recombinant DNA techniques in the development of viral vaccines
EP0120906B1 (en) Polypeptides useful in vaccination against enteroviruses
Zuckerman New hepatitis B vaccines
Dreesman et al. Immunization of chimpanzees with hepatitis B virus-derived polypeptides
WO1991003255A1 (en) Polypeptide vaccines against foot-and-mouth disease virus
Bachrach Foot-and-mouth disease and its antigens
US5182211A (en) Plasmid vectors encoding a protein of a picornavirus
WO1988010298A1 (en) Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies
Zuckerman Subunit, recombinant and synthetic hepatitis B vaccines
Hoatlin et al. Regions of poliovirus protein VP1 produced in Escherichia coli induce neutralizing antibodies
AU619477B2 (en) Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies
Arai et al. Demonstration of non-infections hemagglutinating particles of rabies virus and isolation of the hemagglutinin by disruption of the virion with Nonidet P-40
Brown Foot-and-mouth disease virus
AU2001276182B2 (en) Improved virus like particles based on small envelope protein from hepatitis B (HBsAg-S)
FI80466B (fi) Syntetisk picornavirus vaccin och antigen.
Epstein Vaccination against Epstein-Barr virus
Dreesman et al. Hepatitis B surface antigen Polypeptide and synthetic peptide vaccines

Legal Events

Date Code Title Description
MKEX Expiry